ABNORMAL INSULIN SECRETION IN PARKINSON'S DISEASE BEFORE AND DURING l-DIHYDROXYPHENYLALANINE (l-DOPA) THERAPY

1973 ◽  
Vol 59 (3) ◽  
pp. 523-534 ◽  
Author(s):  
M. H. VAN WOERT ◽  
P. S. MUELLER ◽  
L. M. AMBANI ◽  
U. RATHEY

SUMMARY Insulin and glucose metabolism were studied in parkinsonian patients before and during treatment with l-DOPA and in a chronically ill, elderly, control group of patients. The parkinsonian patients had a low absolute glucose disappearance rate and a low serum insulin response to intravenous glucose compared with controls, which was not altered by l-DOPA therapy. The serum glucose and insulin responses to the oral glucose tolerance tests in parkinsonian patients were similar to those of the control group. Normal immediate insulin responses were observed after infusions of tolbutamide and glucagon. l-DOPA decreased serum insulin and glucose levels during the first 90 min of the oral glucose tolerance test and produced an increase in concentration of human growth hormone in serum of some parkinsonian patients. l-DOPA therapy had no effect on intravenous tolbutamide and glucagon tolerance tests. Our results indicate a selective defect in the mechanism of intravenous glucose-induced insulin release in patients with Parkinson's disease.

1998 ◽  
Vol 80 (4) ◽  
pp. 323-331 ◽  
Author(s):  
David L. Frape ◽  
Norman R. Williams ◽  
Jayshri Rajput-Williams ◽  
B. W. Maitland ◽  
A. J. Scriven ◽  
...  

Twenty-four middle-aged healthy men were given a low-fat high-carbohydrate (5.5 g fat; L), or a moderately-fatty, (25.7 g fat; M) breakfast of similar energy contents for 28 d. Other meals were under less control. An oral glucose tolerance test (OGTT) was given at 09.00 hours on day 1 before treatment allocation and at 13.30 hours on day 29. There were no significant treatment differences in fasting serum values, either on day 1 or at the termination of treatments on day 29. The following was observed on day 29: (1) the M breakfast led to higher OGTT C-peptide responses and higher areas under the curves (AUC) of OGTT serum glucose and insulin responses compared with the OGTT responses to the L breakfast (P< 0.05); (2) treatment M failed to prevent OGTT glycosuria, eliminated with treatment L; (3) serum non-esterified fatty acid (NEFA) AUC was 59% lower with treatment L than with treatment M, between 09.00 and 13.20 hours (P<0.0001), and lower with treatment L than with treatment M during the OGTT (P= 0.005); (4) serum triacylglycerol (TAG) concentrations were similar for both treatments, especially during the morning, but their origins were different during the afternoon OGTT when the Svedberg flotation unit 20–400 lipid fraction was higher with treatment L than with treatment M (P= 0.016); plasma apolipoprotein B-48 level with treatment M was not significantly greater than that with treatment L (P= 0.086); (5) plasma tissue plasminogen-activator activity increased after breakfast with treatment L (P= 0.0008), but not with treatment M (P= 0.80). Waist:hip circumference was positively correlated with serum insulin and glucose AUC and with fasting LDL-cholesterol. Waist:hip circumference and serum TAG and insulin AUC were correlated with factors of thrombus formation; and the OGTT NEFA and glucose AUC were correlated. A small difference in fat intake at breakfast has a large influence on circulating diurnal NEFA concentration, which it is concluded influences adversely glucose tolerance up to 6 h later.


Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 2158-2158
Author(s):  
Mohamed A. Yassin ◽  
Ahmed M Elawa ◽  
Ashraf T Soliman

Abstract Abstract 2158 Introduction: Both insulin deficiency and insulin resistance are reported in patients with β thalassemia major (BTM). The use of continuous blood glucose monitoring system (CGMS) among the different methods for early detection of glycaemic abnormalities has not been studied thoroughly in these patients. Aims: The aims of this study were: 1. to detect glycaemic abnormalities, if any, in young adults with BTM using fasting blood glucose (FBG), oral glucose tolerance test (OGTT), 72-h continuous glucose concentration by CGMS system, and serum insulin and C-peptide concentrations 2. To compare the results of these two methods in detecting glycaemic abnormalities in these patients and 3. To calculate homeostatic model assessment (HOMA), and the quantitative insulin sensitivity check index (QUICKI) in these patients. In order to evaluate whether glycaemic abnormalities are due to insulin deficiency and/or resistance. Materials and methods: Randomly selected young adults (n = 14) with BTM were the subjects of this study. All patients were investigated using a standard oral glucose tolerance test (OGTT) (using 75 gram of glucose) and 72-h continuous glucose concentration by CGM system (Medtronic system). Fasting serum insulin and C-peptide concentrations were measured and HOMA-B, HOMA-IR were calculated accordingly. Results: Using OGTT, 5 patients had impaired fasting glucose (IFG) (Fasting BG from 5.6 to 6.9 mmol/L). Two of them had impaired glucose tolerance IGT (BG from 7.8 and < 11.1 mmol/L) and one had BG = 16.2 mmol/L after 2-hrs (diabetic). Using CGMS in addition to the glucose data measured by glucometer (3–5 times/ day), 6 patients had IFG. The maximum (postprandial) BG recorded exceeded 11.1 mmol/L in 4 patients (28.5%) (Diabetics) and was > 7.8 but < 11.1 mmol/L in 8 patients (57%) (IGT). The mean values of HOMA and QUICKI in patients with BTM were < 2.6 (1.6± 0.8) and > 0.33 (0.36±0.03) respectively ruling out significant insulin resistance in these adolescents. There was a significant negative correlation between the β-cell function (B %) on the one hand and the fasting and the 2-h BG (r= −0.6, and − 0.48, P< 0.01 respectively) on the other hand. Serum insulin concentrations were not correlated with fasting BG or ferritin levels. The average and maximum BG levels recorded by CGMS were significantly correlated with the fasting BG (r= 0.69 and 0.6 respectively with P < 0.01) and with the BG at 2-hour after oral glucose intake (r= 0.87and 0.86 respectively with P < 0.01). Ferritin concentrations were positively correlated with the fasting BG and the 2-h BG levels in the OGTT (r= 0.69, 0.43 respectively, P < 0.001) as well as with the average and the maximum BG recorded by CGM (r =0.75, and 0.64 respectively with P < 0.01). Ferritin concentrations were negatively correlated with the β-cell function (r= −0.41, P< 0.01). Conclusion: CGMS has proved to be superior to OGTT for the diagnosis of glycaemic abnormalities in young adult patients with BTM. In our patients, defective β-cell function rather than insulin resistance appeared to be the cause for these abnormalities. The significant correlations between serum ferritin concentrations and the beta cell functions suggested the importance of adequate chelation to prevent β-cell dysfunction Disclosures: No relevant conflicts of interest to declare.


1971 ◽  
Vol 67 (2) ◽  
pp. 277-287 ◽  
Author(s):  
E. Nieschlag ◽  
B. Wördehoff ◽  
H. J. Gilfrich ◽  
J. Michaelis ◽  
C. Overzier

ABSTRACT The influence of antithyroid therapy on the abnormalities of carbohydrate metabolism observed in hyperthyroidism was investigated in 10 patients. No history of diabetes mellitus was known in the patients or their families. 9 normal persons were taken as a control group. An oral and an intravenous glucose tolerance test were administered prior to and at intervals of 2 and 4 weeks after initiation of therapy. Prior to treatment an inpairment of oral glucose tolerance was observed, whereas the glucose assimilation coefficient in the intravenous glucose tolerance test was normal. Both tests however, revealed a significant rise in insulin values above normal. 2 weeks after initiation of therapy insulin values returned to normal during the intravenous glucose tolerance test. During the oral glucose tolerance test glucose and insulin concentration achieved normal levels only after 4 weeks of treatment. In all patients the abnormalities of carbohydrate metabolism observed were reversible.


1985 ◽  
Vol 248 (5) ◽  
pp. E500-E506 ◽  
Author(s):  
E. Ionescu ◽  
J. F. Sauter ◽  
B. Jeanrenaud

The effect of intravenous glucose or tolbutamide administration on plasma glucose and insulin levels was compared with that following spontaneous ingestion of glucose in freely moving 6- to 7-wk- and 13- to 14-wk-old lean and obese (fa/fa) rats. Irrespective of age, the obese rats had a normal blood glucose tolerance when glucose or tolbutamide load was given intravenously, whereas the glucose ingestion [oral glucose tolerance test (OGTT) caused a marked glucose intolerance that became more pronounced with the duration of the syndrome. This suggests that factors other than insulin resistance could play a role in the occurrence of abnormal OGTT in obese rats. When blood insulin levels were expressed as percent change over base line and when compared with age-matched normal rats, the 6- to 7-wk obese rats showed a normal and even higher beta-cell responsiveness to intravenous or oral glucose as well as to tolbutamide. In contrast, the 13- to 14-wk obese rats presented a decreased beta-cell responsiveness to all such stimuli. Thus the beta-cell function of obese rats worsens with time. Inasmuch as 13- to 14-wk-old obese fa/fa rats have insulin resistance, high basal glycemia, and abnormal oral glucose tolerance, they can be viewed as a potential model of type II diabetes.


Sign in / Sign up

Export Citation Format

Share Document